{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:47:02Z","timestamp":1768524422345,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ahj.2014.06.026","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T18:00:48Z","timestamp":1405101648000},"page":"530-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis"],"prefix":"10.1016","volume":"168","clinical-trial-number":[{"clinical-trial-number":"nct01774955","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Dimitrios","family":"Alexopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Xanthopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin P.","family":"Bliden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2014.06.026_bb0005","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.06.026_bb0010","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.026_bb0015","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.026_bb0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1538-7836.2007.02812.x","article-title":"The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score","volume":"6","author":"Geisler","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.06.026_bb0025","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2014.06.026_bb0030","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2012.11.040","volume":"61","author":"Frelinger","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.026_bb0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2013.03.037","article-title":"The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study","volume":"62","author":"Gurbel","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.026_bb0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjcard.2012.08.043","article-title":"Prasugrel monitoring and bleeding in real world patients","volume":"111","author":"Cayla","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2014.06.026_bb0050","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.2174\/13816128113199990002","article-title":"Factors affecting residual platelet aggregation in prasugrel treated patients","volume":"19","author":"Alexopoulos","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ahj.2014.06.026_bb0055","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: the ONSET\/OFFSET Study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.06.026_bb0060","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.026_bb0065","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.06.026_bb0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","article-title":"Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study","volume":"60","author":"Alexopoulos","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.06.026_bb0075","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/dc12-2510","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes mellitus","volume":"36","author":"Alexopoulos","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2014.06.026_bb0080","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ijcard.2013.01.191","article-title":"Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients","volume":"168","author":"Alexopoulos","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2014.06.026_bb0085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/jth.12095","article-title":"Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients","volume":"11","author":"Alexopoulos","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.06.026_bb0090","first-page":"1743.e13","article-title":"Platelet reactivity measurements reveal patient noncompliance during ticagrelor maintenance therapy","volume":"29","author":"Alexopoulos","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ahj.2014.06.026_bb0095","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.thromres.2013.04.030","article-title":"Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention","volume":"132","author":"Laine","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2014.06.026_bb0100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1538-7836.2011.04604.x","article-title":"High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low?","volume":"10","author":"Jeong","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.06.026_bb0105","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3109\/09537104.2011.579203","article-title":"Modification of the VerifyNow\u00ae P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism","volume":"22","author":"Jakubowski","year":"2011","journal-title":"Platelets"},{"key":"10.1016\/j.ahj.2014.06.026_bb0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ahj.2012.03.022","article-title":"Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies","volume":"164","author":"Jeong","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.06.026_bb0115","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00228-012-1227-4","article-title":"Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals","volume":"68","author":"Teng","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2014.06.026_bb0120","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.06.026_bb0130","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.964395","article-title":"Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"5","author":"Husted","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2014.06.026_bb0135","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-013-0987-8","article-title":"Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients","author":"Wagner","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ahj.2014.06.026_bb0145","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.amjcard.2009.07.015","article-title":"Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention","volume":"104","author":"Bonello-Palot","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2014.06.026_bb0150","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.06.026_bb0155","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"32","author":"Becker","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.06.026_bb0165","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ahj.2012.06.005","article-title":"Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"164","author":"Cornel","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2014.06.026_bb0170","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1160\/TH13-08-0642","article-title":"Unraveling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors","volume":"111","author":"Gurbel","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2014.06.026_bb0175","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","article-title":"Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment","volume":"54","author":"Angiolillo","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2014.06.026_bb0180","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2014.06.026_bb0185","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","article-title":"Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome","volume":"63","author":"Bonello","year":"2014","journal-title":"J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870314004128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870314004128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:53:11Z","timestamp":1757569991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870314004128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0002870314004128"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2014.06.026","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2014.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}